IP Library Granted Patent US 9,487,477
Granted Patent B2
US 9,487,477 · App. 15/012,625 · Granted Nov 8, 2016

Crystalline phase of (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) with L-lysine

Inventors: Fabrice Balavoine (Paris, FR); Jean-Marie Schneider (Magnanville, FR); Gérard Coquerel (Boos, FR); Nicolas Couvrat (Les Damps, FR)
Assignee: Quantum Genomics
C07C319/28C07C227/42C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,487,477
App. No.
15/012,625
Granted
Nov 8, 2016
Kind
B2
Abstract

The present invention relates to a new crystalline phase of (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and its use, particularly in the pharmaceutical industry, and to processes for preparation thereof. The invention is also directed to pharmaceutical compositions containing at least one crystalline phase of (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and to the therapeutic or prophylactic use of such crystalline phase and compositions comprising the same.

Claims (8)

1. A process for the preparation of a crystalline form of (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1 -sulfonic acid) and L-lysine, comprising the steps of:

a) contacting an aqueous solution of (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid), or a salt thereof, or mixtures thereof, with an aqueous solution of L-lysine to form a mixed solution, wherein the (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid):L-lysine stoichiometry is between about 1:1.5 and 1:2.5.;

b) adding an excess of an anti-solvent to the mixed solution formed in step a to form a crystalline phase of (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) L-lysine;

c) optionally improving the crystallinity of the crystalline phase by subjecting said crystalline phase to temperature cycling between 20 and 50° C.; and

d) isolating the crystalline phase obtained in step (b) or step (c).

2. The process according to claim 1 , wherein the anti-solvent is ethanol.

3. The process according to claim 1 , wherein the temperature cycling is repeated several times.

4. The process according to claim 2 , wherein the temperature cycling is repeated between 5 and 15 times.

Priority Claims (1)
EP 12306307 · Oct 22, 2012 · regional
Continuity (2)
Division 14437343
Related Publication 20160221940A1 · Aug 4, 2016